# Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

> **NCT01934452** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 77 (actual)

## Conditions studied

- Complete Remission in Renal Cell Carcinoma

## Interventions

- **DRUG:** sunitinib
- **DRUG:** sunitinib

## Key facts

- **NCT ID:** NCT01934452
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-21
- **Primary completion:** 2022-01-19
- **Final completion:** 2022-01-19
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01934452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01934452, "Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01934452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*